$TMDX
TransMedics Group, Inc.

2021 Q3 Form 10-Q Financial Statement

#000156459021055805 Filed on November 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q2
Revenue $5.370M $7.091M $3.391M
YoY Change -24.27% -1.58% -40.15%
Cost Of Revenue $1.597M $2.050M $1.480M
YoY Change -22.1% -31.42% -36.48%
Gross Profit $3.773M $5.038M $1.909M
YoY Change -25.11% 19.5% -42.72%
Gross Profit Margin 70.26% 71.05% 56.3%
Selling, General & Admin $10.34M $5.490M $5.870M
YoY Change 88.25% -15.78% -6.08%
% of Gross Profit 273.92% 108.97% 307.49%
Research & Development $5.163M $4.160M $3.900M
YoY Change 24.11% -15.77% -18.58%
% of Gross Profit 136.84% 82.57% 204.3%
Depreciation & Amortization $455.0K $400.0K $380.0K
YoY Change 13.75% 17.65% 35.71%
% of Gross Profit 12.06% 7.94% 19.91%
Operating Expenses $15.50M $9.650M $9.770M
YoY Change 60.6% -15.78% -11.5%
Operating Profit -$11.73M -$4.610M -$7.861M
YoY Change 154.34% -36.34% 2.02%
Interest Expense -$1.228M -$470.0K -$630.0K
YoY Change 161.28% -143.36% -27.59%
% of Operating Profit
Other Income/Expense, Net -$1.228M $0.00 $0.00
YoY Change -100.0% -100.0%
Pretax Income -$12.95M -$5.080M -$8.491M
YoY Change 154.98% -38.57% -7.56%
Income Tax $9.000K $10.00K $10.00K
% Of Pretax Income
Net Earnings -$12.96M -$5.088M -$8.497M
YoY Change 154.76% -38.55% -7.59%
Net Earnings / Revenue -241.38% -71.75% -250.58%
Basic Earnings Per Share -$0.47
Diluted Earnings Per Share -$467.9K -$187.4K -$0.36
COMMON SHARES
Basic Shares Outstanding 27.70M 23.33M
Diluted Shares Outstanding 27.70M

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $102.9M $132.7M $139.4M
YoY Change -22.49% 50.28% 44.91%
Cash & Equivalents $22.50M $21.40M $51.15M
Short-Term Investments $80.36M $111.3M $88.20M
Other Short-Term Assets $3.703M $2.300M $1.900M
YoY Change 61.0% 9.52% 18.75%
Inventory $14.87M $13.00M $12.60M
Prepaid Expenses
Receivables $4.150M $6.100M $4.400M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $125.6M $154.1M $158.2M
YoY Change -18.51% 43.48% 36.22%
LONG-TERM ASSETS
Property, Plant & Equipment $5.063M $4.700M $4.400M
YoY Change 7.72% 0.0% 0.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $506.0K $500.0K $500.0K
YoY Change 1.2% 8233.33% 8233.33%
Total Long-Term Assets $5.569M $5.200M $4.900M
YoY Change 7.1% 0.0% 0.39%
TOTAL ASSETS
Total Short-Term Assets $125.6M $154.1M $158.2M
Total Long-Term Assets $5.569M $5.200M $4.900M
Total Assets $131.1M $159.3M $163.1M
YoY Change -17.67% 41.47% 34.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.682M $800.0K $3.700M
YoY Change 235.25% -83.33% -44.46%
Accrued Expenses $12.77M $11.50M $8.900M
YoY Change 11.03% 23.66% 8.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $15.92M $13.60M $13.80M
YoY Change 17.08% -7.11% -10.26%
LONG-TERM LIABILITIES
Long-Term Debt $35.06M $34.53M $34.40M
YoY Change 1.54% 1.48% 1.47%
Other Long-Term Liabilities $1.616M $1.600M $1.200M
YoY Change 1.0% 220.0% 100.0%
Total Long-Term Liabilities $35.06M $34.53M $35.60M
YoY Change 1.54% 1.48% 5.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.92M $13.60M $13.80M
Total Long-Term Liabilities $35.06M $34.53M $35.60M
Total Liabilities $52.60M $49.77M $49.40M
YoY Change 5.68% 1.27% -0.91%
SHAREHOLDERS EQUITY
Retained Earnings -$429.8M -$391.9M
YoY Change 9.67% 8.77%
Common Stock $501.5M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $78.55M $109.6M $113.8M
YoY Change
Total Liabilities & Shareholders Equity $131.1M $159.3M $163.1M
YoY Change -17.68% 41.47% 34.79%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$12.96M -$5.088M -$8.497M
YoY Change 154.76% -38.55% -7.59%
Depreciation, Depletion And Amortization $455.0K $400.0K $380.0K
YoY Change 13.75% 17.65% 35.71%
Cash From Operating Activities -$9.350M -$6.410M -$8.540M
YoY Change 45.87% 14.67% -29.77%
INVESTING ACTIVITIES
Capital Expenditures -$68.00K -$50.00K -$120.0K
YoY Change 36.0% 66.67% -20.0%
Acquisitions
YoY Change
Other Investing Activities $6.267M -$23.42M -$40.60M
YoY Change -126.76% 25.04% -17.06%
Cash From Investing Activities $6.199M -$23.47M -$40.73M
YoY Change -126.41% 25.11% -17.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 552.0K -180.0K 75.55M
YoY Change -406.67% -92.59% -21.38%
NET CHANGE
Cash From Operating Activities -9.350M -6.410M -8.540M
Cash From Investing Activities 6.199M -23.47M -40.73M
Cash From Financing Activities 552.0K -180.0K 75.55M
Net Change In Cash -2.599M -30.06M 26.28M
YoY Change -91.35% 12.25% -24.57%
FREE CASH FLOW
Cash From Operating Activities -$9.350M -$6.410M -$8.540M
Capital Expenditures -$68.00K -$50.00K -$120.0K
Free Cash Flow -$9.282M -$6.360M -$8.420M
YoY Change 45.94% 14.39% -29.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2021Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
103891000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
372000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
211000
CY2021Q1 tmdx Adjustments To Common Stock Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToCommonStockShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1112000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7917000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
97675000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
213000
CY2021Q2 tmdx Adjustments To Common Stock Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToCommonStockShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1808000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
344000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
208000
CY2021Q3 tmdx Adjustments To Common Stock Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToCommonStockShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1973000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-12962000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
78549000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
197000
CY2020Q1 tmdx Adjustments To Common Stock Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToCommonStockShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
385000
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
16000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
213000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8852000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
46683000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
92000
tmdx Stock Issuance Costs And Discounts
StockIssuanceCostsAndDiscounts
628000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75042000
CY2020Q2 tmdx Adjustments To Common Stock Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToCommonStockShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
631000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-42000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-149000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8497000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
113760000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
160000
CY2020Q3 tmdx Reversal Of Estimated Offering Costs
ReversalOfEstimatedOfferingCosts
43000
CY2020Q3 tmdx Adjustments To Common Stock Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToCommonStockShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
700000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
16000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-68000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-5088000
us-gaap Profit Loss
ProfitLoss
-22437000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1147000
us-gaap Share Based Compensation
ShareBasedCompensation
1716000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
705000
tmdx Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
2249000
tmdx Repayment Of Paycheck Protection Program Loan
RepaymentOfPaycheckProtectionProgramLoan
2249000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75516000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
398000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1305000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21897000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
26000
us-gaap Profit Loss
ProfitLoss
-31500000
CY2020 us-gaap Profit Loss
ProfitLoss
-28700000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-429800000
CY2021Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
102900000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21717000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20139000
tmdx Clinical Trial Expense
ClinicalTrialExpense
1100000
CY2020Q3 tmdx Clinical Trial Expense
ClinicalTrialExpense
900000
tmdx Clinical Trial Expense
ClinicalTrialExpense
2100000
CY2021Q3 tmdx Customer Payments Recorded As Operating Expenses
CustomerPaymentsRecordedAsOperatingExpenses
400000
tmdx Customer Payments Recorded As Operating Expenses
CustomerPaymentsRecordedAsOperatingExpenses
1600000
CY2020Q3 tmdx Customer Payments Recorded As Operating Expenses
CustomerPaymentsRecordedAsOperatingExpenses
300000
tmdx Clinical Trial Expense
ClinicalTrialExpense
1123000
tmdx Clinical Trial Expense
ClinicalTrialExpense
2127000
CY2021Q3 us-gaap Revenues
Revenues
5370000
CY2020Q3 us-gaap Revenues
Revenues
7091000
us-gaap Revenues
Revenues
20594000
tmdx Customer Payments Recorded As Operating Expenses
CustomerPaymentsRecordedAsOperatingExpenses
1100000
us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
Payment terms for customer orders, including for each of the Company’s primary performance obligations, are typically 30 days for customers in the United States and 30 to 90 days for customers in non-U.S. markets, and such payments do not include payments that are variable, dependent on specified factors or events.
CY2021Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2020Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
us-gaap Revenue Performance Obligation Description Of Timing
RevenuePerformanceObligationDescriptionOfTiming
The Company generally satisfies performance obligations within one year of the contract inception date.
CY2021Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
800000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5413000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7973000
us-gaap Revenues
Revenues
18012000
CY2021Q3 us-gaap Revenues
Revenues
5370000
CY2020Q3 us-gaap Revenues
Revenues
7091000
us-gaap Revenues
Revenues
20594000
us-gaap Revenues
Revenues
18012000
CY2021Q3 us-gaap Revenues
Revenues
5370000
CY2020Q3 us-gaap Revenues
Revenues
7091000
us-gaap Revenues
Revenues
20594000
us-gaap Revenues
Revenues
18012000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4030000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
981000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
344000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2975000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1517000
CY2021Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12769000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
10317000
CY2020Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1400000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2826044
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2331920
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
80359000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
80360000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
101050000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
101061000
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
88472000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
114890000
CY2021Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7198000
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6770000
CY2021Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1790000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1102000
CY2021Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5881000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4062000
CY2021Q3 us-gaap Inventory Net
InventoryNet
14869000
CY2020Q4 us-gaap Inventory Net
InventoryNet
11934000
tmdx Inventory Transfer To Property Plant And Equipment
InventoryTransferToPropertyPlantAndEquipment
900000
tmdx Inventory Transfer To Property Plant And Equipment
InventoryTransferToPropertyPlantAndEquipment
700000
CY2021Q3 tmdx Accrued Research Development And Clinical Trials Expenses Current
AccruedResearchDevelopmentAndClinicalTrialsExpensesCurrent
4505000
CY2020Q4 tmdx Accrued Research Development And Clinical Trials Expenses Current
AccruedResearchDevelopmentAndClinicalTrialsExpensesCurrent
4426000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4308000
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
35000000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
35000000
CY2021Q3 tmdx Long Term Debt Noncurrent Before Debt Discount And Accrued Payments
LongTermDebtNoncurrentBeforeDebtDiscountAndAccruedPayments
35000000
CY2020Q4 tmdx Long Term Debt Noncurrent Before Debt Discount And Accrued Payments
LongTermDebtNoncurrentBeforeDebtDiscountAndAccruedPayments
35000000
CY2021Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
593000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
834000
CY2021Q3 us-gaap Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
651000
CY2020Q4 us-gaap Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
491000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
35058000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
34657000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote on all matters submitted to a vote of the Company’s shareholders.
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1973000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
700000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4893000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1716000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
21300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2021Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
500000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1400000
CY2021Q3 tmdx Tenant Improvements Allowance Receivable
TenantImprovementsAllowanceReceivable
100000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
476000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1948000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1997000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2047000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2098000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
4354000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2021Q1 us-gaap Recorded Unconditional Purchase Obligation
RecordedUnconditionalPurchaseObligation
9500000
CY2021Q1 tmdx Recorded Unconditional Purchase Commitment Maturity Year And Month
RecordedUnconditionalPurchaseCommitmentMaturityYearAndMonth
2029-12
CY2021Q3 us-gaap Noncurrent Assets
NoncurrentAssets
5063000
CY2020Q4 us-gaap Noncurrent Assets
NoncurrentAssets
4754000

Files In Submission

Name View Source Status
0001564590-21-055805-index-headers.html Edgar Link pending
0001564590-21-055805-index.html Edgar Link pending
0001564590-21-055805.txt Edgar Link pending
0001564590-21-055805-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmdx-10q_20210930.htm Edgar Link pending
tmdx-10q_20210930_htm.xml Edgar Link completed
tmdx-20210930.xsd Edgar Link pending
tmdx-20210930_cal.xml Edgar Link unprocessable
tmdx-20210930_def.xml Edgar Link unprocessable
tmdx-20210930_lab.xml Edgar Link unprocessable
tmdx-20210930_pre.xml Edgar Link unprocessable
tmdx-ex311_7.htm Edgar Link pending
tmdx-ex312_8.htm Edgar Link pending
tmdx-ex321_9.htm Edgar Link pending
tmdx-ex322_6.htm Edgar Link pending